Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder.
Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday.
The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French drugmaker’s lead therapy.
Photo: AFP
Still, Sanofi probably needs Dupixent to also perform well in the related trial, called Notus, before it can apply for approval, said Tim Anderson, an analyst at Wolfe Research LLC.
That study likely would not produce key data until next year.
This is the first time an antibody therapy has shown to be effective against COPD and follows stumbles from AstraZeneca PLC’s drug Fasenra and GSK PLC’s Nucala, Peter Welford of Jefferies said in a recent note.
In the trial, Dupixent improved people’s lung function and quality of life.
The results are “unprecedented and potentially paradigm-shifting,” Dietmar Berger, Sanofi’s chief medical officer, said in the statement.
Common among current and former smokers, among others, COPD damages people’s lungs and can cause persistent coughing and breathlessness, along with anxiety, depression and sleep disturbances.
In the US, about 300,000 people suffer from the type of COPD that was included in this trial, Sanofi said.
There have been no new treatment approaches approved for COPD in more than a decade, Sanofi said.
Sanofi has developed Dupixent with the US company Regeneron Pharmaceuticals Inc. The French company has a peak sales forecast of more than 13 billion euros (US$14.2 billion) for the drug, which does not include any potential revenue for treating COPD.
Some analysts are forecasting that Dupixent would bring in as much as 18 billion euros in sales by 2030.
PATENTS: MediaTek Inc said it would not comment on ongoing legal cases, but does not expect the legal action by Huawei to affect its business operations Smartphone integrated chips designer MediaTek Inc (聯發科) on Friday said that a lawsuit filed by Chinese smartphone brand Huawei Technologies Co (華為) over alleged patent infringements would have little impact on its operations. In an announcement posted on the Taiwan Stock Exchange, MediaTek said that it would not comment on an ongoing legal case. However, the company said that Huawei’s legal action would have little impact on its operations. MediaTek’s statement came after China-based PRIP Research said on Thursday that Huawei filed a lawsuit with a Chinese district court claiming that MediaTek infringed on its patents. The infringement mentioned in the lawsuit likely involved
Taipei is today suspending work, classes and its US$2.4 trillion stock market as Typhoon Gaemi approaches Taiwan with strong winds and heavy rain. The nation is not conducting securities, currency or fixed income trading, statements from its stock and currency exchanges said. Authorities had yesterday issued a warning that the storm could affect people on land and canceled some ship crossings and domestic flights. Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) expects its local chipmaking fabs to maintain normal production, the company said in an e-mailed statement. The main chipmaker for Apple Inc and Nvidia Corp said it has activated routine typhoon alert
GROWTH: TSMC increased its projected revenue growth for this year to more than 25 percent, citing stronger-than-expected demand for AI devices and smartphones The Taiwan Institute of Economic Research (TIER, 台灣經濟研究院) yesterday raised its forecast for Taiwan’s GDP growth this year from 3.29 percent to 3.85 percent, as exports and private investment recovered faster than it predicted three months ago. The Taipei-based think tank also expects that Taiwan would see a 8.19 percent increase in exports this year, better than the 7.55 percent it projected in April, as US technology giants spent more money on artificial intelligence (AI) infrastructure and development. “There will be more AI servers going forward, but it remains to be seen if the momentum would extend to personal computers, smartphones and
Catastrophic computer outages caused by a software update from one company have once again exposed the dangers of global technological dependence on a handful of players, experts said on Friday. A flawed update sent out by the little-known security firm CrowdStrike Holdings Inc brought airlines, TV stations and myriad other aspects of daily life to a standstill. The outages affected companies or individuals that use CrowdStrike on the Microsoft Inc’s Windows platform. When they applied the update, the incompatible software crashed computers into a frozen state known as the “blue screen of death.” “Today CrowdStrike has become a household name, but not in